1031P ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors

Autor: Calvo, E., Joerger, M., Läubli, H., Lopez, J.S., Alonso, G., Corral de la Fuente, E., Hess, D., König, D., Perez, V., Gasal, E., Jethwa, S., Di Blasi, D., Garralda, E.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S626-S627

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

Autor: Melichar, B., Bracarda, S., Matveev, V., Alekseev, B., Ivanov, S., Zyryanov, A., Janciauskiene, R., Fernebro, E., Mulders, P.F.A., Osborne, S., Jethwa, S., Mickisch, G., Gore, M., Moorselaar, R.J.A. van, Staehler, M., Magne, N., Bellmunt, J., Investigators, B.E.

Publikováno v: Melichar, B, Bracarda, S, Matveev, V, Alekseev, B, Ivanov, S, Zyryanov, A, Janciauskiene, R, Fernebro, E, Mulders, P, Osborne, S, Jethwa, S, Mickisch, G, Gore, M, van Moorselaar, R J A, Staehler, M, Magne, N & Bellmunt, J 2013, ' A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN ', Annals of Oncology, vol. 24, no. 9, pp. 2396-2402 . https://doi.org/10.1093/annonc/mdt228
Annals of Oncology, 24, 2396-402
Annals of Oncology, 24, 9, pp. 2396-402
Annals of Oncology, 24(9), 2396-2402. Oxford University Press

Item does not contain fulltext BACKGROUND: Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha2a (IFN; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ac9c1a4f7e9ff0c59dc3764667ca8de
https://doi.org/10.1093/annonc/mdt228

A Comparison between BTA and Amidoximes and their Interactions with Copper Surfaces

Autor: Jethwa, S., Tee, D.W., Francis, S.M., Grillo, F., Richardson, N.V., Reid, Chris, McGhee, Larry, Lee, W.M.

Publikováno v: Diffusion and Defect Data Part B: Solid State Phenomena; April 2012, Vol. 187 Issue: 1 p231-234, 4p

7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN

Autor: Bracarda, S., Bellmunt, J., Negrier, S.N., Melichar, B., Ravaud, A., Jethwa, S., Sneller, V., Escudier, B.

Publikováno v: In EJC Supplements 2009 7(2):431-431

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.